Blue Trust Inc’s Third Harmonic Bio THRD Stock Holding History

Blue Trust Inc’s Portfolio THRD Stock Details THRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-58	Closed	-$754	–	2951
2024 Q3	$754	Buy	+58	New	+$719	﹤0.01%	2743

Other funds holding THRD

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Blue Trust Inc's THRD Position: Q4 2024 in Review

Blue Trust Inc sold out of Third Harmonic Bio (THRD) in Q4 2024, closing a stake of 58 shares — an estimated $754 sold.

Blue Trust Inc first reported a position in THRD in Q3 2024 and held it in 1 quarter. The position peaked at $754 in Q3 2024. 96 funds tracked by Wall St. Rank hold THRD as of Q4 2024.

Blue Trust Inc reported no remaining Third Harmonic Bio position as of Q4 2024 after selling out during the quarter.
Blue Trust Inc sold 58 Third Harmonic Bio shares in Q4 2024, an estimated $754.
Blue Trust Inc first reported a position in Third Harmonic Bio in Q3 2024 and held it in 1 quarter.
Blue Trust Inc's Third Harmonic Bio position peaked at $754 in Q3 2024.
96 funds tracked by Wall St. Rank held Third Harmonic Bio as of Q4 2024.

Based on Blue Trust Inc's 13F filing for Q4 2024, filed 22 Jan 2025.